
IN8BIO (INAB) Stock Forecast & Price Target
IN8BIO (INAB) Analyst Ratings
Bulls say
IN8bio Inc demonstrates a positive outlook due to the promising efficacy of its lead product candidate, INB-100, which has shown a 100% overall survival rate at one year in high-risk acute myeloid leukemia (AML) patients undergoing haploidentical stem cell transplantation, significantly surpassing the historical 70% survival rate. The company’s ongoing multi-center expansion cohort study is expected to further validate these results, as it enrolls more patients and aims for completion in 2025. Additionally, the favorable safety profile of INB-100, with no reported treatment-related deaths or severe side effects, bolsters investor confidence in the product's potential for successful commercialization.
Bears say
IN8bio Inc's outlook is negatively impacted by a reduced price target of $6.00, down from $8.00, indicating diminished investor confidence in the company's financial prospects. Despite some potential shown by INB-619 in preclinical studies, the overall commercial viability of its gamma-delta T cell product candidates faces significant uncertainty, particularly given the competitive landscape in oncology. Furthermore, the company's reliance on early-stage product candidates, such as INB-400 and INB-100, contributes to heightened financial risks associated with clinical trial outcomes and long-term market acceptance.
This aggregate rating is based on analysts' research of IN8BIO and is not a guaranteed prediction by Public.com or investment advice.
IN8BIO (INAB) Analyst Forecast & Price Prediction
Start investing in IN8BIO (INAB)
Order type
Buy in
Order amount
Est. shares
0 shares